PHARMING GRP SP. ADRS (PHG) - Total Liabilities
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has total liabilities worth €222.86 Million EUR (≈ $260.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does PHARMING GRP SP. ADRS generate cash to assess how effectively this company generates cash.
PHARMING GRP SP. ADRS - Total Liabilities Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's total liabilities have evolved over time, based on quarterly financial data. Check PHARMING GRP SP. ADRS liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PHARMING GRP SP. ADRS Competitors by Total Liabilities
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HDC Holdings Co Ltd
KO:012630
|
Korea | ₩7.76 Trillion |
|
Atal SA
WAR:1AT
|
Poland | zł3.25 Billion |
|
Anshan Senyuan Road Bridge
SHE:300210
|
China | CN¥587.19 Million |
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
China | CN¥749.46 Million |
|
EuroTeleSites AG
F:7YF
|
Germany | €1.69 Billion |
|
Zhejiang Henglin Chair Industry Co Ltd Class A
SHG:603661
|
China | CN¥6.72 Billion |
|
Metallus, Inc
NYSE:MTUS
|
USA | $455.20 Million |
|
People & Technology Inc
KQ:137400
|
Korea | ₩1.14 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down PHARMING GRP SP. ADRS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PHG stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHARMING GRP SP. ADRS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual total liabilities of PHARMING GRP SP. ADRS from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €222.86 Million ≈ $260.55 Million |
+24.56% |
| 2024-12-31 | €178.92 Million ≈ $209.18 Million |
-26.69% |
| 2023-12-31 | €244.07 Million ≈ $285.35 Million |
+10.36% |
| 2022-12-31 | €221.16 Million ≈ $258.56 Million |
+8.20% |
| 2021-12-31 | €204.40 Million ≈ $238.96 Million |
-- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more